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Insulin-like growth factor 2 mRNA binding protein 3
(IGF2BP3) expression correlates with malignancy,
but its role(s) in pathogenesis remains enigmatic. We
interrogated the IGF2BP3-RNA interaction network
in pancreatic ductal adenocarcinoma (PDAC) cells.
Using a combination of genome-wide approaches,
we have identified 164 direct mRNA targets of
IGF2BP3.These transcripts encodeproteins enriched
for functions such as cell migration, proliferation, and
adhesion. Loss of IGF2BP3 reduced PDAC cell inva-
siveness and remodeled focal adhesion junctions.
Individual nucleotide resolution crosslinking immu-
noprecipitation (iCLIP) revealed significant overlap
of IGF2BP3 and microRNA (miRNA) binding sites.
IGF2BP3 promotes association of the RNA-induced
silencing complex (RISC) with specific transcripts.
Our results show that IGF2BP3 influences a ma-
lignancy-associated RNA regulon by modulating
miRNA-mRNA interactions.INTRODUCTION
RNA binding proteins (RBPs) and microRNAs (miRNAs) are the
central mediators of post-transcriptional gene regulation (Gerst-
berger et al., 2014). Like transcription factors, RBPs andmiRNAs
coordinate expression of proteinswith related functions (Blackin-
ton and Keene, 2014; Keene, 2007). These regulatory factors
often converge on the 30 UTRs of mRNAs (Jens and Rajewsky,
2015). Juxtaposition of their binding sites contributes to combi-
natorial mechanisms of post-transcriptional gene regulation
(Glorian et al., 2011; Zhang et al., 2008; Kundu et al., 2012; Young
et al., 2012; Kim et al., 2009; Jafarifar et al., 2011; Ho et al., 2013).1876 Cell Reports 15, 1876–1883, May 31, 2016 ª 2016 The Author(s
This is an open access article under the CC BY-NC-ND license (http://IGF2BP1, -2, and -3 are a family of structurally and functionally
related RBPs with developmentally regulated expression pat-
terns (Yaniv and Yisraeli, 2002). IGF2BP3 is of particular interest
because it is undetectable in most adult tissue but strongly ex-
pressed in embryos and in diverse tumor types (Mueller-Pillasch
et al., 1999; Ko¨bel et al., 2009; Schaeffer et al., 2010; Findeis-
Hosey and Xu, 2011). For example, it is upregulated in 90% of
pancreatic ductal adenocarcinomas, suggesting that it may
have a role in initiation or progression of cancer (Schaeffer
et al., 2010). Several groups proposed that elevated IGF2BP3
expression is prognostic for malignancy in PDAC, colorectal,
ovarian cancers, and B-acute lymphocytic leukemia (B-ALL)
and negatively influences patient survival (Suvasini et al., 2011;
Stoskus et al., 2011; Schaeffer et al., 2010; Lochhead et al.,
2012; Ko¨bel et al., 2009; Bell et al., 2013). Indeed, Taniuchi
et al. demonstrated aberrant IGF2BP3 expression in pancreatic
tumors promotes metastasis in xenograft assays in nude mice
(Taniuchi et al., 2014). It is likely that this role of IGF2BP3 in can-
cer metastasis mirrors a normal function of IGF2BP3-mediated
cell migration during embryogenesis (Mueller et al., 2003; Muel-
ler-Pillasch et al., 1999).
The evidence for IGF2BP3 acting as a bona fide pathoprotein
continues to mount (Wagner et al., 2003; Palanichamy et al.,
2016), yet several fundamental questions remain unanswered.
For example, IGF2BP3 regulates cytoplasmic steps of post-tran-
scriptional gene expression, but the molecular mechanisms are
unknown (Nielsen et al., 1999; Vikesaa et al., 2006; Jønson et al.,
2014; Gu et al., 2012). Another challenge is elucidating the RNA
binding specificity of IGF2BP3 in cancer cells. Recent studies
identified transcripts associated with exogenous or endogenous
IGF2BP3 using photo activated ribonucleoside (PAR)-CLIP and
RIP-seq (Hafner et al., 2010; Taniuchi et al., 2014). Here, we
use a combination of genomic approaches to discover cancer-
related IGF2BP3 mRNA targets. These data also suggest a
mechanism for IGF2BP3-dependent gene regulation. We find
that IGF2BP3 modulates the association of target transcripts).
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. IGF2BP3 Regulates Transcripts
Associated with Cancer Pathways
(A) Volcano plot depicting differentially expressed
genes from both PANC1 and PL45 (blue dots) and
those mRNAs bound by IGF2BP3 (orange dots).
(B) Bar graph showing relative quantification of
mRNA levels in IGF2BP3-depleted or control
PANC1 cells.
(C) KEGG pathway enrichment analysis of differen-
tially expressed-IGF2BP3 bound mRNAs (orange
dots from A).
(D) Gene Ontology enrichment analysis of differ-
entially expressed-IGF2BP3 bound mRNAs.
(E) Genome Browser snapshots of read coverage
from replicate RIP-seq experiments from PL45
cells for CD44 and CLDN1 30 UTR (top and bottom,
respectively).
(F) Relative quantification qRT-PCR analysis of
CD44 and CLDN1 mRNA stability in control or
IGF2BP3-depleted PL45 cells.
(G) Bar graph quantifying the invasiveness of
control or IGF2BP3-depleted PANC1 or PL45 cells
through Matrigel filters relative to control filters.
Bars represent an average of three independent
experiments. Error bars correspond to SD. Sta-
tistical significance was estimated using an un-
paired t test (***p < 0.001, *p < 0.05).with the RNA-induced silencing complex (RISC). Taken together,
our results reveal a malignancy associated RNA network regu-
lated by IGF2BP3.
RESULTS
Identification of IGF2BP3 mRNA Targets in PDAC Cells
To characterize the mRNA targets of IGF2BP3, we performed
RIP-seq in two PDAC cell lines. We identified 2,223 and 1,718
transcripts enriched in the anti-IGF2BP3 immunoprecipitate
relative to the control from PL45 and PANC1 cells, respectively
(Figure S1; Table S1). A significant fraction of the PANC1 target
transcripts (1,069, or 63%; Figure S1D) were also identified in
the PL45 RIP dataset (odds-ratio = 14.2, p < 1.50e-195, Fisher’s
exact test). This common set of transcripts encodes proteinsCell Rover-represented for functions in focal
adhesion junctions, cell migration, and
regulation of the actin cytoskeleton (see
Table S2). Included in this common set
are CD44, HMGA2, EIF4EBP2, ARF6,
and ARHGEF4, previously characterized
as IGF2BP3 targets (Vikesaa et al., 2006;
Jønson et al., 2014; Taniuchi et al., 2014;
Mizutani et al., 2015)
To identify IGF2BP3 regulatory targets,
we analyzed steady-state mRNA levels
in IGF2BP3-depleted and control PDAC
cells (PL45 and PANC1 cell lines) using
high-throughput RNA sequencing (RNA-
seq). Differential expression sequencing
(DESeq) analysis revealed 2,795 differen-tially expressed PANC1 genes (Figure 1A; Table S3). We vali-
dated several candidate genes from PANC1 cells by RT-qPCR.
Of the 10 transcripts selected for validation, 9 agreed with the
RNA-Seq data (Figure 1B). In PL45 cells, DESeq identified 137
differentially expressed transcripts (Table S3). We obtained
similar results using Affymetrix exon arrays (Figure 1A; Table
S4). Of the 137 differentially expressed genes in PL45 cells, 53
were also identified in the PANC1 experiment (p < 0.0001,
Fisher’s exact test). Comparison of control PANC1 and PL45
revealed thousands of differentially expressed genes, suggest-
ing that these cell models are quite different (Table S5; Ryu
et al., 2002) To identify direct IGF2BP3 regulatory targets, we
focused on differentially expressed transcripts that are repro-
ducibly associated with IGF2BP3 in RIP-seq assays (Figure 1A,
orange dots). This approach revealed 164 transcripts encodingeports 15, 1876–1883, May 31, 2016 1877
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Figure 2. Global Single-Nucleotide-Resolution IGF2BP3-RNA Interaction Map
(A) Bar graph showing genomic distribution of IGF2BP3 from PDAC cell lines, hnRNPA1 (HEK293 cells), and simulated (hg19 background) crosslinking sites. The
bars represent the average of replicate experiments (n = 2 from PL45; n = 1 from PANC1), respectively. SDs are indicated by error bars.
(B) Distribution of peaks called from IGF2BP3-, hnRNPA1- and simulated crosslinking sites within mRNA.
(C) Meta-analysis of IGF2BP3 and hnRNPA1 iCLIP crosslink sites relative to the stop codon. Relative crosslinking density (normalized count) is shown ±SEM.
(D) IGF2BP3 crosslinking density from PDAC cell lines mapped relative to annotated miRNA target sites. hnRNPA1 crosslinking sites from HEK293 cells are
included as a control.
(E) Overrepresented pentamers found near IGF2BP3 crosslinking sites in PDAC cells.proteins enriched for functions in cancer pathways, cellular
migration/motility, and regulation of the actin cytoskeleton (Fig-
ures 1C and 1D, adjusted p < 0.05; Table S2).
We investigated how IGF2BP3 affects steady-state mRNA
levels using the PL45 cell model. In PL45 cells, as previously
described for HeLa cells (Vikesaa et al., 2006), IGF2BP3-deple-
tion correlates with reduced mRNA levels of the bona fide target
CD44 (Tables S1 and S3). Previous studies determined that
IGF2BP3 stabilizes CD44 mRNA (Vikesaa et al., 2006). We
used actinomycin D to inhibit transcription and measure the
decay rate of CD44 and three additional targets, ANTRX1,
CLDN1, and OLR1 mRNAs. As expected, we confirmed that
CD44 mRNA is less stable in IGF2BP3-depleted cells. Likewise,
ANTRX1 mRNA also has a shorter half-life in IGF2BP3-depleted
cells relative to control cells. By contrast, decay of CLDN1 and
OLR1 mRNA is attenuated when IGF2BP3 is depleted from
PL45 cells (Figures 1E and 1F).
IGF2BP3 Modulates Focal Adhesions and Promotes
PDAC Cell Invasiveness
To determine how IGF2BP3 expression influences cancer cell
biology, we analyzed focal adhesion junctions and cell migration
in control or IGF2BP3-depleted PDAC cells (Figure S2). Genes
from both of these pathways are enriched in the IGF2BP3-RNA1878 Cell Reports 15, 1876–1883, May 31, 2016interaction network (Figures 1C and 1D; Table S2). We stained
focal adhesion complexes with antibody recognizing focal adhe-
sion kinase (FAK). Although FAK staining localizes to the periph-
ery of both control and IGF2BP3-depleted cell lines, their size
difference was significant in IGF2BP3-depleted cells relative to
control (Figures S2D and S2E; p < 0.0020, Student’s t test). To
determine whether depletion of IGF2BP3 affects the invasive
behavior of PDAC cells, we performed in vitro invasion assays.
IGF2BP3-depleted cells exhibited significantly reduced inva-
siveness as compared to control cells (Student’s t test, p <
0.01 for both lines; Figures 1G and S2C). Taken together, these
data show that IGF2BP3 alters the focal adhesion junction and
promotes PDAC invasiveness in vitro.
A Single-Nucleotide-Resolution Map of IGF2BP3-RNA
Interactions
We used individual nucleotide resolution CLIP (iCLIP) to deter-
mine in situ binding specificity of IGF2BP3 in PL45 and PANC1
cells. Anti-IGF2BP3 antibodies precipitated nuclease-sensitive
protein-RNAcomplexes fromwhole cell extracts of UV-irradiated
cells (Figures S3A–S3C). We obtained three libraries from two
replicate experiments from PL45 and a single PANC1 assay.
We identified 244 and 124mRNA targets that directly crosslinked
with IGF2BP3 in PL45 and PANC1 cells, respectively (Table S6).
AB
C
D
Figure 3. IGF2BP3 Modulates Expression of miRNA-Regulated
Transcripts
(A) Examples of miRNA families with significant sequence similarity between
their target site and the IGF2BP3 consensus motif (left panel). Enrichment of
miRNA target sites in 30 UTRs identified by iCLIP and by RNA-seq analysis of
control or IGF2BP3-depleted PANC1 cells.
(B) UCSC genome browser screen shots showing read coverage across
miRNA-9 and -128 loci (top and bottom, respectively). Histogram shows
number of reads at each position. Sequence conservation across 100 verte-
brate genomes (navy blue track).
(C) Schematic diagram of luciferase reporter plasmids.
(D) Scatterplot showing normalized luciferase reporter expression (fold repres-
sion) in control cells (orange) and IGF2BP3-depleted cells (blue).Unique reads from the IGF2BP3 iCLIP libraries map with high
frequency to exonic sequences. This distribution differs from
another RBP, hnRNPA1, which crosslinks to intronic sequences
(Figure 2A). A background set of simulated crosslinking sites
map primarily to intergenic regions (Figure 2A). We annotated
IGF2BP3, hnRNPA1 and simulated binding sites using the
Piranha peak caller software (Uren et al., 2012). Both IGF2BP3
and hnRNPA1 peaks occur with highest frequency in 30 UTRs
of target transcripts (Figure 2B). By contrast, simulated data
exhibit a larger proportion of peaks in first and internal exons.
IGF2BP3 binding sites occur frequently within 30 UTRs.We hy-
pothesized that cis-regulatory signals associated with 30 UTR
overlap IGF2BP3 binding sites. To test this hypothesis, we
refined the IGF2BP3-RNA interaction map by isolating the 50
end of each read. These positions correspond to the protein-
RNA crosslink site. We determined crosslinking frequency rela-
tive to cis-acting RNA elements within 30 UTRs (Figures 2C and
2D). IGF2BP3 and hnRNPA1 crosslinking density relative to
stop codons is similar (Figure 3C). By contrast, crosslinking
density for IGF2BP3, but not hnRNPA1, peaked within a 25-bp
window centered on predicted miRNA target sequences (Fig-
ure 2D). These data suggest that IGF2BP3 binding is specifically
enriched over predicted miRNA target sites. Next, we used
IGF2BP3 crosslink sites to identify overrepresented motifs using
a pentamer-clustering approach (see Experimental Procedures).
Two overrepresentedmotifs occur within a 10-nt window of each
crosslinking site. One motif resembles a previously defined
IGF2BP3 consensus binding sequence (Figure 2E, bottom;
Table S7; Hafner et al., 2010). Our results are also consistent
with a bipartite motif described for IGF2BP1 (Chao et al.,
2010). Approximately 50%–70% of the PL45 and PANC1 iCLIP
targets significantly overlapped the RNA immunoprecipitation
and high throughput sequencing (RIP-seq) data (Fisher’s exact
test p < 2.74 e19 and 1.0 e90, respectively; Figures S3F,
S3J, and S3K). These cross-validated IGF2BP3 targets encode
proteins with functions in cellular adhesion, migration, and
remodeling of the extracellular matrix (Figure S3G).
IGF2BP3-RNA crosslinks overlap miRNA targets sites in 30
UTRs. We determined if IGF2BP3 shares sequence specificity
with miRNAs. We scored 221 miRNA seed-target site pairings
(Lewis et al., 2005) by their similarity to IGF2BP3-bound pentam-
ers (see Experimental Procedures). miRNAs score significantly
higher if their target site crosslinks to IGF2BP3 than isolated sites
(Figure 3A; Table S8; p < 0.00153, Wilcoxon rank-sum test).
Specific miRNA target sites are overrepresented in both theCell Reports 15, 1876–1883, May 31, 2016 1879
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Figure 4. IGF2BP3 Alters mRNA Association with RISC
(A) Western blot of Ago2 immunoprecipitation from control (NT) or IGF2BP3-
depleted (KD) PANC1 cells.
(B–F) qRT-PCR analysis of RNA precipitated with a-Ago2 or nonspecific rabbit
IgG (Ago2 RIP or IgG RIP, respectively). Relative quantification for each tran-
script was performed using 18S rRNA as a reference gene. Statistical signifi-
cance was estimated for each comparison using an unpaired t test (*p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001).
1880 Cell Reports 15, 1876–1883, May 31, 2016iCLIP data andwithin the 30 UTRs of differentially expressed tran-
scripts in PANC1 cells (Figure 3A, gray boxes; Figures S3H and
S3I; Tables S9 and S10). These include miR-1, -9, -17, -20A/B,
-19A/B, -106, -128A/B, -181, -200B/C, -429, and -506, among
others. Small RNA-seq confirmed the expression of this subset
of miRNA in PANC1 cells (Figure 3B; Table S11).
RBPs can stabilize mRNA by competing with miRNAs for
common regulatory motifs (Jens and Rajewsky, 2015). To test
this hypothesis, we re-examined IGF2BP3-dependent changes
in steady-state mRNA levels. Transcripts targeted by both
IGF2BP3 andmiRNAs tended toward a reduction in steady state
mRNA levels. By contrast, transcripts containing only miRNA-
target sites were largely unaffected by IGF2BP3 depletion (Fig-
ure S3I). These data suggest that IGF2BP3 may attenuate
miRNA-mediated mRNA decay. To further determine if IGF2BP3
antagonizes specific miRNAs, we generated luciferase mRNA
reporters containing exact matches to miR-9 and -128 in their
30 UTR (Figure 3C). Both miRNAs target a sequence predicted
to bind IGF2BP3. If the attenuation model is correct, we predict
IGF2BP3-depletion would result in a significant decrease in
luciferase reporter expression. In wild-type cells, both miR-9
and -128 reporters showed significant repression relative to
the control reporter construct (Figure 3D; p < 0.0022). By
contrast, repression of miR-9 and -128 luciferase reporters
was significantly attenuated in IGF2BP3-depleted cells (Fig-
ure 3D, compare repression of miR-9 and -128 in IGF2BP3-de-
peleted or control cells; p < 0.0022).
IGF2BP3 Promotes Ago2-mRNA Interactions
The data presented above suggest that IGF2BP3may function in
concert with the RISC in PDAC cells. We tested this hypothesis
by immunoprecipitating Argonaute 2 (Ago2), a RISC component
(Gerstein et al., 2010), from control or IGF2BP3-depleted PANC1
cells and further quantified co-purified mRNA by qRT-PCR.
Western blotting confirmed precipitation of Ago2 from both con-
trol and IGF2BP3-depleted cells (Figure 4A). TBP and HMGA2
mRNAs served as controls for this experiment. TBP mRNA
was not detected in any of the IGF2BP3 protein-RNA interaction
assays (iCLIP or RIP), and its steady-state mRNA levels are
not affected by IGF2BP3 depletion (Figure S4). By contrast,
HMGA2 is a bona fide IGF2BP3-regulatory target. IGF2BP3 sta-
bilizes HMGA2mRNA by antagonizing its association with RISC
(Jønson et al., 2014). BesidesHMGA2, we selected several other
IGF2BP3-bound transcripts for analysis including ZFP36L1,
DCBLD2, and CLDN1. IGF2BP3 depletion correlates with
increased ZFP36L1, DCBLD2, and CLDN1 mRNA levels and
decreasedHMGA2mRNA (Figure S4). All the mRNAs co-precip-
itate with Ago2 from both control and knockdown cells (Figure 4,
compare Ago2-RIP to immunoglobulin G [IgG]). TBP mRNA
binding to Ago2 was independent of IGF2BP3 protein levels
(Figure 4B). As expected, HMGA2 mRNA co-precipitation with
Ago2 increased in IGF2BP3-depleted cells (Figure 4C). However,
Ago2’s association with ZFP36L1,DCBLD2, andCLDN1mRNAs
diminished. (Figures 4D–4F; p < 0.0161, 0.0135 and 0.0144,
respectively). These data show that IGF2BP3 is a bimodal modu-
lator of the RISC-mRNA association.
DISCUSSION
In this study, we identify a set of IGF2BP3 mRNA targets
enriched in cancer-related pathways including focal adhesions,
adherens junctions, actin-cytoskeleton, and cell migration. The
IGF2BP3 RNA regulon reported here is strikingly similar to
the homologous Drosophila protein IMP (dIMP) (Hansen et al.,
2015). Our study provides evidence that IGF2BP3 and miRNAs
converge on the 30 UTRs of target transcripts to coordi-
nately up- and downregulate programs of gene expression that
are associated with malignancy and invasiveness. The results
further show that this dual activity of IGF2BP3 likely operates
through its ability to protect transcripts from, or enhance,
miRNA-mediated post-transcriptional gene silencing.
The expression of IGF2BP3 correlates with malignancy. Eluci-
dating direct IGF2BP3-mRNA targets is a major challenge for the
field (Bell et al., 2013). Earlier studies identified thousands of
IGF2BP3 targets using highly sensitive assays with low speci-
ficity (Taniuchi et al., 2014; Hafner et al., 2010). Here, we delin-
eate a refined set of mRNA targets by integrating different
genomic approaches. A similar strategy significantly reduced
the mRNA target space for HuR and hnRNP H1 (Uren et al.,
2016; Mukherjee et al., 2011). This integrated approach to eluci-
dating IGF2BP3 target transcripts was also applied to human
B-ALL cells (Palanichamy et al., 2016). We identified a regulon
of similar size (216 transcripts in B-ALL cells versus 164 in
PDAC cells) but with very different classes of enriched tran-
scripts such as cell-cycle regulation and blood cell differentiation
(Palanichamy et al., 2016). Further, a significant fraction (65%)
of the B-ALL targets are downregulated upon IGF2BP3 deple-
tion. These data suggest a role for IGF2BP3 in mRNA stabiliza-
tion in B-ALL cells. It will be interesting to determine how
IGF2BP3 activities are defined in different cell types.
miRNAmodulation is amajor function of RBPs (Ho et al., 2013;
Kundu et al., 2012; Kedde et al., 2007; Jafarifar et al., 2011; Bhat-
tacharyya et al., 2006; Jing et al., 2005; Xue et al., 2013).
IGF2BP3 promotes mRNA stability, as described for CD44
and HMGA2 (Vikesaa et al., 2006; Jønson et al., 2014). One
mechanism suggested by Jønson et al., and partially supported
by our iCLIP data, is that in certain contexts miRNAs and
IGF2BP3 compete for common binding sites within 30 UTRs.
The sequence similarity between the consensus IGF2BP3 RNA
recognition elements and target sites of several different miRNA
families support this hypothesis (Figure 3) as does the concom-
itant decrease in expression of mRNAs that are targeted by both
regulatory systems (Figure S3I). However, our miRNA reporters
and Ago2 RIP experiments revealed an unexpected role for
IGF2BP3 in promoting the association of mRNAs with Ago2 (Fig-
ures 3D and 4). The mechanism we propose here is consistent
with a recent finding that IGF2BP3 destabilizes the EIF4EBP2
mRNA in HeLa cells (Mizutani et al., 2015).Our results demonstrate that IGF2BP3 is a bi-modal regulator
of target mRNA stability. It remains to be determined how the
dual roles of IGF2BP3 in mRNA stability are regulated and
if IGF2BP3 has different functions in different types of cancer
cells. Other RBPs, including HuR, PTB, MOV10, and FMRP,
function as bi-modal modulators of RISC function (Kenny et al.,
2014; Kim et al., 2009; Kundu et al., 2012; Mukherjee et al.,
2011; Young et al., 2012; Xue et al., 2013). Given that several
of the miRNA families presented in Figure 3C play roles in cancer
cell biology, it is possible that the modulation of RISC by
IGF2BP3 contributes to PDAC pathogenesis.
EXPERIMENTAL PROCEDURES
Cell Lines and Constructs
We maintained PDAC cell lines, PL45 and PANC1, according to the recom-
mended conditions (ATCC). We created independent clones of IGF2BP3-
depleted or control cell lines by transfecting PDAC cells with plasmids that
express IGF2BP3-targeting short hairpin RNA or a non-targeting control
(Santa Cruz Biotechnology) with Lipofectamine 2000 (Life Technologies) and
selecting with puromycin (1 mg/ml).
Western Blot and Antibodies
We performed western blotting as previously described (Sterne-Weiler et al.,
2011). We probed nitrocellulose filters with the following antibodies against
IGF2BP3 (clone D7, Santa Cruz), GAPDH (clone FL335, Santa Cruz), hnRNPA1
(clone 4B10, Santa Cruz), and anti-4EBP (clone D-10, Santa Cruz).
Immunofluorescence Microscopy
Cells grown on acid-washed, fibronectin-coated coverslips were fixed in 4%
paraformaldehyde in PBS for 15 min and washed in PBS for 10 min and
0.15 M glycine in PBS for 10 min on a shaker. Cells were permeabilized in
0.02% Triton in PBS for 10 min with a subsequent wash in PBS for another
10 min. Coverslips were blocked using 10% serum (to secondary host animal)
in PBS and incubated with primary antibodies (anti-FAK [C-20, Santa Cruz]
and anti-IGF2BP3 [N-19, SantaCruz]) diluted in 5%serum in a humidified cham-
ber for 12 hr at 4C.After threewashes inPBS for 15mineach, the sampleswere
incubated with secondary antibody and a nuclear stain diluted in 5% serum for
45min in a humidified chamber at room temperature. All samplesweremounted
onto slideswith Fluoromount-G (SouthernBiotech) andallowed todry overnight.
Slides were imaged on Keyence Biorevo BZ-9000 digital widefield microscope.
Invasion Assay
In vitro invasion assay used transwell inserts with 8.0-mm pore size according to
the manufacturer’s protocol (BD Biosciences). Each transwell insert (Matrigel
coated or control) received 5 3 105 PDAC cells suspended in serum-free me-
dium. The transwell inserts were then placed into six-well plates containing me-
diumsupplementedwith 10%FBS. After 72 hr, we removed cells from the upper
surface of the transwell inserts and fixed/stained cells on the lower surface using
theQuik-Diff kit andDAPI (IMEB).WecountedDAPIstainednuclei fromfourfields
of each well using an inverted microscope and ImageJ software. We performed
each experiment in triplicate.
Gene Expression Profiling of PDAC Cells by RNA-Seq
We isolated RNA from cytosolic fractions of IGF2BP3-depleted or control
PANC1 and PL45 cells using TRI-Reagent LS (Sigma). Illumina-compatible
sequencing libraries were prepared using the NEXTflex Rapid Directional
qRNA-SeqKit (BIOOScientific). We analyzed each condition in duplicate using
the HiSeq2500 platform. miRNA expression was profiled in PANC1 cells using
the NEXTflex small RNA-seq kit v2 (BIOO Scientific). miRNA expression was
analyzed in triplicate. Mapping statistics can be found in Table S12.
RIP-Seq Assay
RNA immunoprecipitation with anti-IGF2BP3 (RN009P, MBL) or normal rabbit
IgG (AB-105-C, R&D Systems) was performed with PL45 and PANC1 cells asCell Reports 15, 1876–1883, May 31, 2016 1881
previously described (Uren et al., 2016). Each RIP and control immunoprecip-
itation was performed in duplicate (PL45) or triplicate (PANC1). Mapping
statistics can be found in Table S12.
iCLIP Assay
iCLIP was performed as previously described using PL45 and PANC1 cells
(Ko¨nig et al., 2010). Two replicate experiments were performed in PL45 cells
and one experiment was performed in PANC1. The three datasets were pooled
for analysis. Mapping statistics can be found in Table S12.
cDNA Synthesis and qRT-PCR
cDNA was synthesized from RNA purified from cytosolic extracts and RIP
samples using the high-capacity cDNA reverse transcriptase kit from ABI Sci-
entific. qPCR was performed using a Roche Lightcycler 480 (Roche Diagnos-
tics), Titanium Taq (Clontech Laboratories), and SYBR green dye. Based on
melting point analysis, primers corresponding to TBP1, CLDN1, ZFP36L1,
DCBDL2, FAT1, DSG2, TFPI2, GJA1, HMGA2, IGF2BP3, and 18S rRNA
generated a single specific amplicon. Primer sequences can be found in Sup-
plemental Experimental Procedures. For normalization, TBP was used as a
reference gene for comparisons in cytoplasmic RNA, whereas 18S rRNA
was used in the RIP experiments. To compare TBP levels between cells,
the geometric mean of three stable genes (CFL1, RHOA, and EGFR) was
used as a reference. Relative expression levels were determined using
the DDCT method with the Roche Lightcycler Analysis Software Package
version 1.5 (Roche Diagnostics). All experiments use a minimum of three
technical replicates per sample and at least three biological replicates per
analysis. Statistical significance was determined by comparing the mean
normalized ratios of each mRNA using a non-parametric Mann-Whitney
U test (Prism6, GraphPad Software).
Ago2 RNA Immunoprecipitation
To immunoprecipitate Ago2 mouse monoclonal antibody 9E8.2 (Millipore)
was tethered to Dynal protein A beads using a rabbit anti-mouse IgG
bridging antibody (Jackson ImmunoResearch, Fcg Fragment Specific).
Mouse IgG (Pierce Biotechnology) was used as a negative control for RIP
assays. Beads were washed three times in lysis buffer (25 mM Tris-HCl
[pH 8.0], 150 mM NaCl, 2 mM MgCl2, 0.5% NP-40, and 5 mM DTT) to re-
move the unbound antibody. Whole-cell extracts were prepared from
IGF2BP3-depleted or control PANC1 cells by lysing cells on ice for 10 min
in 1 ml fresh lysis buffer with protease inhibitors (Complete Protease Inhibitor
Cocktail Tablets, EDTA-free, Roche Applied Science) and RNasin (1/1,000
dilution; Applied Biosystems), followed by sonication and centrifugation at
10,000 3 g for 10 min. Following the washes in lysis buffer (as described
in Supplemental Experimental Procedures), beads were treated with 5 U
RQ DNase I (Promega) for 10 min at 37C. An aliquot from each immunopre-
cipitation was used for western blot analysis, and RNA was purified from the
remainder using TRIzol LS (Invitrogen). Total RNA from cell lysates was iso-
lated using the same procedure and was also subjected to DNA digestion as
described above prior to cDNA synthesis.
iCLIP, RIP, mRNA, and miRNA-Seq Data Analysis Pipeline
Bioinformatic analyses are described in Supplemental Experimental
Procedures.
Luciferase Reporter Assays
Luciferase reporters (pMIR, Life Scientific) containing sequences with perfect
complementarity to miR-9 and 128 in their 30UTR were transfected into
control or IGF2BP3-depleted PANC1 cells using Lipofectamine 2000 (Life
Scientific). Renilla luciferase reporter plasmid (Promega) was cotransfected
as a control for transfection efficiency. Renilla and firefly luciferase activity
was assayed 24 hr post-transfection using the Dual-Glo system (Promega).
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